Qiagen NV

$38.25
(as of Apr 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Qiagen NV

Stock Price
$38.25
Ticker Symbol
QGEN
Exchange
NYSE

Industry Information for Qiagen NV

Sector
Healthcare
Industry
Diagnostics & Research

Company Description for Qiagen NV

Country
USA
Full Time Employees
5,067

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Fundamentals for Qiagen NV

Market Capitalization
$8,724,602,880
EBITDA
$685,225,024
Dividends per Share
$0
P/E Ratio
106.24
Forward P/E Ratio
16.95
Earnings per Share
$0.38
Earnings per Share Estimate Next Year
Profit Margin
4.23%
Shares Outstanding
216,116,000
Percent Owned by Insiders
2.28%
Percent Owned by Institutions
62.13%
52-Week High
52-Week Low

Technical Indicators for Qiagen NV

50-Day Moving Average
200-Day Moving Average
RSI
54.84
0.76

Analyst Ratings for Qiagen NV

Strong Buy
7
Buy
4
Hold
7
Sell
0
Strong Sell
0

News About Qiagen NV

Apr 2, 2025, 6:06 AM EST
Qiagen (NYSE:QGEN) Full Year 2024 Results See more.
Apr 1, 2025, 1:30 AM EST
Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa QIAprep&amp Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure See more.
Mar 31, 2025, 10:00 AM EST
Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. See more.
Mar 31, 2025, 6:00 AM EST
VENLO, Netherlands, March 31, 2025--(BUSINESS WIRE)--QIAGEN N.V. See more.